- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
3D MRI for Quantitative Brain Imaging Gets FDA Nod
SyMRI 3D reportedly combines precise estimates of regional brain volume with improved resolution bolstering accuracy with lesion analysis.
The Food and Drug Administration (FDA) has granted 510(k) clearance for SyMRI 3D, a modality that may offer enhanced resolution and accuracy for brain magnetic resonance imaging (MRI) scans.
Combining quantitative MRI technology with isotropic resolution, SyMRI 3D provides improved accuracy in brain lesion analysis and facilitates brain structure and function assessments through precise brain region volume estimates, according to SyntheticMR U.S., the developer of the SyMRI 3D modality.
The newly FDA-cleared SyMRI 3D reportedly provides improved resolution that enhances accuracy of brain lesion analysis and better precision of brain region volume estimates, according to SyntheticMR U.S., the developer of the modality. (Image courtesy of SyntheticMR U.S.)
“Receiving 510(k) clearance for SyMRI 3D allows us to empower physicians to make more precise and informed decisions in diagnosis and treatment planning through quantitative imaging," said Jared Dixon, the president of SyntheticMR U.S.
SyMRI 3D will also be available to Philips customers as per a recently expanded partnership agreement between the two companies that was announced in November 2023.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
